Urothelial carcinoma in COVID-19: lessons from a pandemic and their impact on clinical practice.
Future Oncol
; 17(32): 4233-4235, 2021 Nov.
Article
in English
| MEDLINE | ID: covidwho-1484983
ABSTRACT
The COVID-19 pandemic has modified the management of urothelial carcinoma (UC). Eighteen months after the onset of the pandemic, a scoping narrative review was able to state that radical cystectomy for UC should not be delayed beyond 10 weeks when neoadjuvant chemotherapy (NAC) was administered and 12 weeks when it was not. NAC should be considered when imminent chemotherapy cannot be performed. Early cystectomy should not be delayed when indicated for patients with high-risk non-MIBC. Patients with non-MIBC should still receive their induction doses of intravesical instillations. Diagnostic cystoscopy should not be deferred in symptomatic patients. Surgical management of upper tract urothelial carcinoma (UTUC) allows for a wider deferral interval.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Urinary Bladder Neoplasms
/
Cystectomy
/
Cystoscopy
/
Time-to-Treatment
Type of study:
Diagnostic study
/
Experimental Studies
/
Prognostic study
/
Reviews
Limits:
Humans
Language:
English
Journal:
Future Oncol
Year:
2021
Document Type:
Article
Affiliation country:
Fon-2021-0895
Similar
MEDLINE
...
LILACS
LIS